key: cord-0701761-khtp8osk
authors: Liu, Shuai; Han, Liping; Li, Jinlong; Li, Hao
title: Electrochemical detection of ACE2 as a biomarker for diagnosis of COVID-19 and potential male infertility
date: 2021-11-19
journal: Biosens Bioelectron
DOI: 10.1016/j.bios.2021.113788
sha: 234cab53b1422d3a4a06b5578c861a39d212d60b
doc_id: 701761
cord_uid: khtp8osk

Knowing how heavily the body is burdened by SARS-CoV-2 infection is all important to avoid tragic outcomes. This demands fast and convenient assays with minimum requirement for instruments and reagents. Therefore, a short synthetic peptide is developed to perform direct serum assay, using portable hand-held potentiostat, in a reagent-less manner. The target is angiotensin converting enzyme 2 (ACE2), a protein secreted by the body into the blood to restrict viral invasion. Specifically, under electrochemical potential scanning, the peptide can covalently capture ACE2 from the serum, and then form a covalent gel-like 2D protein network with the serum proteins, in an ACE2-specific fashion. This formation of a covalent biosensing complex enables sensitive detection in serum samples of SARS-CoV-2 infected patients. The detected serum level of ACE2 can not only serve as an index of viral load, but may also hint at the associated risk of potential male infertility. These results may point to field application of this simple design in the clinical practice in treating COVID-19 in the near future.

Since the pandemic outbreak of COVID-19, the work load of hospital staff around the world has 2 grown exponentially. ( In this work, using simple synthetic chemical probes whose behavior can be electrochemically 21 fine-tuned, an assay for predicting the viral load of SARS-CoV-2 has been developed. In this 22 design, all the biosensing procedures, including signal amplification, can be completed in the 23 clinical serum sample solution. No other reagents, apart from the biosensing electrode, is needed 24 during the detection process. Specifically, the viral marker protein to be assayed is the angiotensin 25 converting enzyme 2 (ACE2), which is now well known to act as the cell membrane entrance for and Lou 2020) To limit viral entry via cell membrane ACE2 and the above associated risk of 32 infertility, the human body elevates the serum level of ACE2 as a defensive measure. Therefore, as 33 indicated by some recent clinical reports, serum ACE2 may serve as the index of viral load and the 34 associated complications. 35

In the design, as shown in Scheme 1, the synthetic probe for detecting ACE2 is tethered on the 36 screen printed electrode surface. This probe is a short peptide sequence that can specifically 37 recognize ACE2, with nano-molar affinity. (Huang et al. 2003 ) But peptide-ACE2 binding does not 38 lead to any readable electrochemical I-V signal readout, and certain mechanism of signal 39 conversion is needed. Since no additional reagents are allowed to enter the biosensing system. The 40 electrochemical device seems to be the only means for signal conversion. So a well-tried method 41

previously employed for sample pre-treatment in mass spectra and liquid chromatography is used: 42 electrochemical scanning between 0.5-1 V can cut peptide strand at the carboxyl end of tyrosine this amino acid. At the same time, the probe-ACE2 molecular recognition also brings the tyrosine 1 moieties on the probe and on the target protein close together. And tyrosine cross-linking through 2 the same electrochemically agitated reactive oxygen species (ROS)-mediated pathway (Larios et al. 3 2001) is also likely to take place between the probe and the target protein. So, the ACE2-free 4 probe molecules on the electrode surface may be discomposed electrochemically, while the 5 ACE2-bound probe molecules may be protected by the partial decomposing of the captured target 6 protein "shielding" the probe from the ROS. In this way, on the one hand, the target protein 7 molecules are covalently immobilized on the electrode surface; on the other hand, all the 8 protein-free probe molecules lose their functional groups to the solution phase. 9

This special functional group, phenyl-urazol,(Alvarez-Dorta et al. 2018) can generate amplified 10 signal, through interacting with all the non-specific interfering serum proteins (mainly albumin). 11

By the above cutting of all these two-headed phenyl-urazol groups into the serum, these 12 cross-linking reagents "released" from the electrode surface can intermingle with the serum 13 proteins. And then, electrochemical scanning over another potential range can induce these 14 cross-linkers to connect with the tyrosine groups on the interfering serum protein molecules, 15 forming a network of proteins. This gel-like formation can be anchored to the electrode surface by 16 the ACE2 proteins already covalently captured there by the previous step. Since all the ACE2-free 17 probes on the electrode have already lost their tyrosine residuals, the protein network can only use 18 the target protein molecules as its foothold points on the surface. So that, higher ACE2 19 concentration in the serum sample can lead to more gel-like network being retained on the 20 electrode surface, after thorough rinsing. Then, the de-natured proteins can generate amplified 21 signal readout proportional to ACE2 abundance, through the electrochemical oxidation of 22 aromatic amino acids exposed by rinsing. The proposed method has been successfully applied in 

The proposed probes, of which the chemical structure was shown in Scheme 1, was 7 custom-synthesized by Science Peptide, Shanghai, as freeze-dried powder, purity > 95%. The 8 powder was dissolved with 100 mM phosphate buffered saline (PBS), pH=7.4, to a concentration 9 of 20 μM, as the stock solution. The human recombinant ACE2 was from R&D system, received 10 as a filtered tris buffer, ACE2 concentration: 200 μM. It was diluted with the above PBS above to 11 a stock solution, with ACE2 at 100 nM. SARS-Cov-2 ELISA assay kit (Elecsys® 12

Anti-SARS-CoV-2 kit) was from Roche, and used following the instruction of the provider. 13

Human recombinant serum albumin was from Albumedix, while human recombinant thrombin 14 was from R&D system. All the stock solutions of the synthetic probe and target proteins were 15 sub-packaged into batches of small vials, to ensure that each vial was just enough for single use, 16 so that freeze-thaw cycles could be completely avoided. All the other reagents were of analytical 17 grade. And the double distilled water for preparing the above solutions was prepared using a 18 MiliQ water purification system, and was purified to a specific conductivity of 18 MΩ/cm. Serum 19 had also been collected from a healthy volunteer for preparing standard samples as detailed below. 20

The clinical samples of serum fractionated from periphery blood of hepatocellular carcinoma 21 patients were retrieved from the sample bank of the biosafety level P2.5 clinical laboratory of

Conductive Indium Tin Oxide (ITO) coated glass was cut to small pieces. For probe 2 immobilization, the ITO glass slide was serially immerged in dd water, ethanol and methanol for 3 bath-supersonicating to remove any organic impurities absorbed on its surface. After 4 bath-sonicating, the slide was thoroughly rinsed with dd water, before being brought to probe 5 modification. The probe contained, at one of its ends, 16-Phosphohexadecanoic acid residuals 6 (Sigma-Aldrich) for self-assembling on the surface of ITO.(Chockalingam et al. 2014) To initiate 7 this process, the stock solution of the probe was dropped on the slide just cleared, and the area 8 covered by the drop of stock solution was then marked out with a mark pen. The self-assembling 9 process was then allowed to proceed for 16 hours at 4 °C in a refrigerator under darkness. The 10 slide was finally rinsed with copious amount of dd water and dried under a stream of high purity 11 nitrogen, before being sent to detect the samples. 12

The slide was used for the interface measurements, namely, the surface plasma resonance and the 14 electrochemical measurements. The samples to be detected came in three different types. The first 15 was the "standard" sample diluted with PBS buffer. The second type was the "serum" sample 16 diluted with the serum of the healthy volunteer. The third kind of sample was the serum from the 17 clinically collected blood. For the standard and serum samples, recombinant ACE2 was employed, 18

for simple quantification, the stock solution of ACE2 was directly diluted. To detect these samples, 19

they were dropped onto the slide, inside the marked-out area, and the mixture was incubated at 20 ambient temperature for proper time as described in the results and discussion. In the detection, 21

after incubation with the sample, current was run through the conductive slide for electrochemical 22 scanning from 0.5~1 V at a voltage scan rate of 0.1 V/s for 10 min, to initiate the electrochemical 23 cleavage of the substrate probe. Then the slide was subject to a second step of electrochemical 24 scanning -0.3~0.9 V to initiate the tyrosine click chemistry, in the presence of 10 μM urazol 25 cross-linker. 26

The MicroCal ITC200 system (GE Healthcare Life Sciences) was used for isothermal titration 28 calorimetry (ITC) measurement. The titration was performed at 25°C. The titration schedule 29 consisted of 38 consecutive 1 μL injections with at least 120 s between each two injections. The 30 heat of dilution measured by titrating over saturation from each data set was subtracted. Before 31 titration, all solutions were degassed. Origin 7.0 software was used to analyze the data. The 32

electrochemical measurement was carried out on a CHI660D potentiostat (CH Instruments) with a 33 conventional three-electrode system: the glass slide was used as the working electrode, the 34 saturated calomel electrode (SCE) was used as the reference electrode, and the platinum wire was water-filled test tube at 60° from the bottom of the test tube for fluorescence measurement. The 7

surface with the gold film should be away from the light source and towards the detector. The 8 activation peak wavelength of di-tyrosine was 325 nm, of Amplex red, was 570 nM. The Atomic 9

force microscopy (AFM) images are recorded using Agilent 5500 AFM system. Samples were 10 imaged at a scan rate of 0.5-1 Hz in a tapping mode. AFM tips with resonant frequency in a range 11 160-260 kHz were used. Images were acquired at a resolution of 512×512 pixels. 12 ACE2 sample is 1 mL. The relative intensity increased significantly due to ACE2 binding 27 specifically to probes on the sensing surface, and the values of the relative intensity were recorded 28 and plotted as a function of time. Then, mild surfactant was pumped into the flow cell to remove and effectively regenerate the sensing surface. The numbered points 0 to 3 represents the start of 1 adding ACE2 (33 nM), the beginning of electrochemical scanning, the adding of mild surfactant, 2 and the adding of de-naturing detergent.

First, the designed probe is studied to verify its ability to specifically target ACE2. In the design, 5 the non-covalent molecular recognition between the peptide probe and ACE2 first brings the two 6 together, and then electrochemical potential scanning induces the cross-linking between the two 7 molecules. So, the molecular recognition is first tested, using isothermal titration calorimetry 8 (ITC), this method measures the heat of reaction when the probe recognizes and interacts with the 9 target protein. More probes will gradually saturate a certain amount of target protein, giving rise to 10 saturation curve. As shown in Figure 1a , a typical saturated binding curve can be observed, 11

indicating relatively strong binding between the probe and ACE2, confirming that the 12 ACE2-targeting ability of the original peptide has not been compromised by adding the images are recorded using Agilent 5500 AFM system. Samples were imaged at a scan rate of 0.5-1 4

Hz in a tapping mode. AFM tips with resonant frequency in a range 160-260 kHz were used. 5

Images were acquired at a resolution of 512×512 pixels. 6 7

Under these optimized conditions, the next step is to use the electrochemical potential scanning 9

to induce cross-linking between the target protein and various serum interfering proteins. For this 10 purpose, the above standard ACE2 sample prepared by diluting with standard PBS buffer is 11 replaced by the serum of a healthy volunteer, while the ferrocene tagged probe is replaced by the 12 designed probe that can release phenyl-urazol cross-linkers after electrochemical scanning. Then, 13

after simple incubation and two subsequent steps of electrochemical scanning in the presence of 14 the sample liquid drop, one between 0.5-1 V, and a second electrochemical scanning between 15 -0.3-0.9 V, the surface of the electrode is examined by atomic force microscopic (AFM) method. 16

As shown in Figure 3a , a dense network-like morphology can be observed on the surface, while a 17 relatively flatter surface can be observed after simple incubation but without electrochemical 18 scanning (Figure 3b ). Cathodic stripping signal is then employed to amplify the readout, as shown 19

in Figure S3 and Figure S4 . Then, quantitative detection of ACE2 in serum diluted sample is performed. As shown in Figure  4 4a, gradual increase of electrochemical current peak signals can be recorded in detecting higher 5 and higher concentrations of ACE2, directly in serum. And a working can be established with a 6 linear range between the signal readout and the logarithm of ACE2 concentration. The standard 7 deviation of all measurements (n=3) is below 5%. Shown in Figure 4b is the specificity with 8 respect to serum interfering species, and it can be seen that only the target protein can induce 9 observable signal readout. Major serum proteins such as albumin, globulins and fibrinogen have 10 been tested, as shown in Figure S5 , and their interfering effect is negligible. Periphery blood 11 sample from SARS-CoV-2 infected patients are collected and detected using the proposed method. 12

As shown in Figure 4c , the level of ACE2 detected is 30~50 times higher than that in the healthy breathing. Future works will focus on discriminate such difference in viral load using the propose 24 method, and on improving the sensitivity of detection beyond that of the commercially available 25 antibody-based methods (Table S1 ). 26 27

In this work, a method for directly assaying a host marker protein of COVID-19 in the periphery 29 blood of SARS-CoV-2 infected patients has been developed. In this method, using only a short 30 peptide sequence that can specifically target ACE2, a glass slide or a screen-printed electrode chip 31 is able to detect the protein in serum, with decent signal amplification enabling a limit of detection 32 in serum as low as 1 pico-molar. Using this method, the clinical serum sample of SARS-Cov-2 33 infected patients can be directly detected, without using any complicated and expensive fixed 34 

Reproductive 21

The 32